You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
英国药厂阿斯利康或就新冠疫苗再进行全球测试
阿思达克 11-27 08:57
英国药厂阿斯利康(AstraZeneca)(AZN.US)行政总裁Pascal Soriot表示,由於新型冠状病毒疫苗的研究结果被外界质疑,有可能会进行另一项全球临床测试,以评估低剂量的疫苗的疗效。

阿斯利康较早时公布的研究结果显示,疫苗的有效率达90%,但这个结果是源於药厂错误地为参加者接种先接受半剂量,然後再接受完整剂量疫苗所得出来的,但接种两剂完整疫苗的有效率却只有62%。

Soriot称,公司已找到成效更大的接种方法,故必须对此进行测试及额外的研究,但不希望额外的测试会阻碍英国及欧洲监管机构对疫苗的批准。

英国政府己要相关部门评估疫苗的临时供应情况,目标於年底前开始推出疫苗,阿斯利康预计到下月底可在英国提供400万剂。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account